Therapeutic targeting of AR in prostate cancer using antiandrogens may be considerably enhanced by targeting of Stat5, through a stimulation of proteosomal degradation of AR liganded by antiandrogens [440]. This evidence concerns the gene AR and Familial prostate cancer.